BACKGROUND: Ovarian Hyperstimulation Syndrome (OHSS) is a severe health complication observed in some patients undergoing hormonal stimulation during IVF. Presence of OHSS is often associated with a high count of growing follicles responding to FSH hyperstimulation. However, the number of responding follicles may not be sufficient enough to predict the onset and severity of OHSS. The aim of this study was to find whether follicular fluid (FF) and serum concentrations of Inhibin A and Inhibin B in patients undergoing IVF treatment may serve as a predictor of OHSS status independent of the growing follicles count. METHODS: Serum and follicular fluid of fifty-three women undertaking the IVF program were separated into four groups according to their OHSS status and growing follicles count and analyzed for serum and FF concentrations of Inhibin A and Inhibin B. The resulting data were combined with clinical and demographic data to calculate indices independent of the growing follicles count. RESULTS: Serum Inhibin A and Inhibin B concentrations showed no significant difference between the severe OHSS group and the control group without OHSS. Moreover, the serum concentrations of Inhibin A and Inhibin B were strongly correlated with the growing follicles count. Their concentrations in the high responders group (>18 follicles) were significantly higher (p < 0.00001, p < 0.0001) when compared with normal and low responders (<18 follicles). To suppress the dependence on the growing follicle count, three indices were constructed and calculated. The best association with OHSS status and independence of the growing follicle count was achieved by using the Inhibin B TFF/SBM index calculated as follows: [concentration in FF] x [growing follicle count]/[concentration in serum] x [body mass]. The Inhibin B TFF/SBM index showed a clear difference (p = 0,00433) between the group with severe OHSS and the control group, while showing no apparent correlation with the growing follicle count. CONCLUSION: These observations demonstrated that while neither serum nor FF concentrations of Inhibin A nor Inhibin B can be used as an OHSS predictor independent of the growing follicle count, calculated indices may meet the criteria.

Assisted Reproduction Centre Department of Obstetrics and Gynecology General Teaching Hospital Prague Czech Republic

Zobrazit více v PubMed

Delvigne A. General definition of the ovarian hyperstimulation syndrome. In: Gerris J, Delvigne A, Olivennes F, editor. Ovarian Hyperstimulation Syndrome. United Kingdom: Informa Healthcare; 2006. pp. 1–5.

Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–261. PubMed

Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, Englert Y, Delbeke L, Darcis L, Gordts S, Puttemans P, Gerris J, Schoysman R, Leroy F. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod. 1993;8:1353–1360. PubMed

Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–440. PubMed

Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9:275–289. doi: 10.1093/humupd/dmg018. PubMed DOI

Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Repro. 2001;12:2491–2495. doi: 10.1093/humrep/16.12.2491. PubMed DOI

Delbaere A, Smits G, De Leener A, Costagliola S, Vassart G. Understanding ovarian hyperstimulation syndrome. Endocrine. 2005;26:285–290. doi: 10.1385/ENDO:26:3:285. PubMed DOI

Pau E, Alonso-Muriel I, Gómez R, Novella E, Ruiz A, García-Velasco JA, Simón C, Pellicer A. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod. 2006;21:1453–1460. doi: 10.1093/humrep/del005. PubMed DOI

Enskog A, Nilsson L, Brannstrom M. Peripheral blood concentrations of inhibin B are elevated during gonadotrophin stimulation in patients who later develop ovarian OHSS and inhibin A concentrations are elevated after OHSS onset. Hum Reprod. 2000;15:52–538. doi: 10.1093/humrep/15.3.532. PubMed DOI

Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril. 2006;85:1541–1543. doi: 10.1016/j.fertnstert.2005.10.052. PubMed DOI

Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, Yang YS, Lee MS. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23:160–167. doi: 10.1093/humrep/dem254. PubMed DOI

Woodruff TK, Mather JP. Inhibin, activin and the female reproductive axis. Annu Rev Physiol. 1995;57:219–244. doi: 10.1146/annurev.ph.57.030195.001251. PubMed DOI

Ericsson GF, Hsueh AJ. Secretion of "inhibin" by rat granulosa cells in vitro. Endocrinology. 1978;103:1960–1963. doi: 10.1210/endo-103-5-1960. PubMed DOI

Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res. 1988;44:1–34. PubMed

Meunier H, Rivier C, Evans RM, Vale W. Gonadal and extragonadal expression of inhibin alpha, beta A, and beta B subunits in various tissues predicts diverse functions. Proc Natl Acad Sci USA. 1988;85:247–251. doi: 10.1073/pnas.85.1.247. PubMed DOI PMC

Kligman I, Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil Steril. 2001;76:1185–1190. doi: 10.1016/S0015-0282(01)02893-X. PubMed DOI

Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk CA. Day 3 Serum Inhibin-B Is Predictive of Assisted Reproductive Technologies Outcome. Fertil Steril. 1997;67:110–114. doi: 10.1016/S0015-0282(97)81865-1. PubMed DOI

Fawzy M, Lambert A, Harrison RF, Knight PG, Groome N, Hennelly B, Robertson WR. Day 5 inhibin B levels in a treatment cycle are predictive of IVF outcome. Hum Reprod. 2002;17:1535–1543. doi: 10.1093/humrep/17.6.1535. PubMed DOI

Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005;112:1384–1390. doi: 10.1111/j.1471-0528.2005.00670.x. PubMed DOI

Creus M, Peñarrubia J, Fábregues F, Vidal E, Carmona F, Casamitjana R, Vanrell JA, Balasch J. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome. Hum Reprod. 2000;15:2341–2346. doi: 10.1093/humrep/15.11.2341. PubMed DOI

Moos J, Filova V, Pavelkova J, Moosova M, Peknicova J, Rezabek K. Follicular fluid and serum levels of Inhibin A and pregnancy-associated plasma protein A in patients undergoing IVF. Fertil Steril. 2009;91:1739–1744. doi: 10.1016/j.fertnstert.2008.01.102. PubMed DOI

Bernard DJ, Chapman SC, Woodruff TK. Mechanisms of inhibin signal transduction. Recent Prog Horm Res. 2001;56:417–450. doi: 10.1210/rp.56.1.417. PubMed DOI

Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol. 2007;15:9. doi: 10.1186/1477-7827-5-9. PubMed DOI PMC

Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18:323–327. doi: 10.1093/humrep/deg042. PubMed DOI

Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod. 1991;6:1395–1399. PubMed

Morris RS, Wong IL, Kirkman E, Gentschein E, Paulson RJ. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod. 1995;10:1355–1358. PubMed

Lockwood GM, Muttukrishna S, Groome NP, Knight PG, Ledger WL. Circulating inhibins and activin A during GnRH-analogue downregulation and ovarian hyperstimulation with recombinant FSH for in-vitro fertilization-embryo transfer. Clin Endocrinol (Oxf) 1996;45:741–748. doi: 10.1046/j.1365-2265.1996.8510861.x. PubMed DOI

Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T. Serum inhibin A, VEGF and TNF levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21:1260–1265. doi: 10.1093/humrep/dei475. PubMed DOI

Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grondahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006;21:2126–2130. doi: 10.1093/humrep/del119. PubMed DOI

Wen X, Tozer AJ, Butler SA, Bell CM, Docherty SM, Iles RK. Follicular fluid levels of inhibin A, inhibin B, and activin A levels reflect changes in follicle size but are not independent markers of the oocyte's ability to fertilize. Fertil Steril. 2006;85:1723–1729. doi: 10.1016/j.fertnstert.2005.11.058. PubMed DOI

Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 1999;71:808–814. doi: 10.1016/S0015-0282(99)00090-4. PubMed DOI

Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 1988;159:210–215. PubMed

Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 1996;81:1401–1405. doi: 10.1210/jc.81.4.1401. PubMed DOI